Hisamitsu announces positive Phase II results for Parkinson's disease drug

10 February 2014

Japanese drugmaker Hisamitsu Pharmaceutical’s (TYO: 4530) has announced the results of a Phase II clinical study for a transdermal drug for the treatment of Parkinson’s disease in Japan

The efficacy and safety of the HP-3000 (ropinirole hydrochloride) were compared with a placebo in patients with Parkinson’s disease who concomitantly used L-dopa (levodopa). A statistically significant difference was confirmed for improvement in the primary efficacy endpoint compared with the placebo group.

The product is a transdermal formulation developed using Hisamitsu’s TDDS (Transdermal Drug Delivery System) technology. Hisamitsu aims to initiate a Phase III clinical study later this year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical